Navigation Links
Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections
Date:7/13/2010

ASHBURN, Va., July 13 /PRNewswire/ -- Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Technologies Ltd., has submitted a Special Protocol Assessment (SPA) for a proposed phase 3 clinical trial to support the U.S. approval of Cogenzia™:  Innocoll's topical antibiotic therapy for the adjuvant treatment of infected diabetic foot ulcers.

The protocol was developed following an End of Phase 2 meeting with FDA where the results of Innocoll's phase 2 clinical studies were presented and discussed. In the planned phase 3 randomized, placebo-controlled, double-blind clinical trial, patients with a moderate or severe diabetic foot infection will be treated with Cogenzia on a daily basis as an adjunct to standard-of-care, which includes systemic antibiotic therapy administered by the oral or intravenous route. Patients will be treated for a maximum of 28 days and the primary endpoint will be the percentage of patients who are clinically cured of infection 10 days after discontinuation of all antibiotic therapy. The study design is based on a highly encouraging phase 2 trial where 100% of Cogenzia-treated patients who completed the study achieved clinical cure, which was statistically significantly superior to 70% of patients in the control group (P = 0.024). Patients in the Cogenzia group also had a significantly higher rate of baseline pathogen eradication and a reduced time to pathogen eradication (P < 0.001).

Dr. Michael Myers, Innocoll's President and CEO commented, "Building on the strength of the phase II data, we continue to make great strides in the development of our lead product, Cogenzia.   We are particularly encouraged by the fact that the product will be developed as adjuvant therapy for use in conjunction with systemic
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
2. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
6. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
10. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
11. Advanced Life Sciences Submits Updated Special Protocol Assessment to FDA for Restanza in Community Acquired Bacterial Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CARLSBAD, Calif. , July 10, 2014 /PRNewswire/ ... products and services, has launched the FreeRunner™ knee ... runners, who suffer from patella mal-tracking return to ... anatomy differently than other braces, providing support when ... move normally when they don,t. Patellofemoral ...
(Date:7/10/2014)...  RESMED INC. (NYSE: RMD ) today announced ... ended June 30, 2014 results on Thursday, July 31, 2014, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the ... MiE America , Inc., a leading provider of ... into a long-term agreement naming BC Technical as the ... MiE and BC Technical announced today ... to establish BC Technical as the service and systems ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... Sept. 1, 2011 Hill-Rom Holdings, Inc., (NYSE: ... management presentation at the Morgan Stanley Global Healthcare Conference ... 8:35 a.m. ET. You are invited to ... at http://ir.hill-rom.com/events.cfm or access it directly at ...
... makers of the ACCU-CHEK® portfolio of diabetes management products ... Infusion Site Awareness Week, Aug. 29-Sept. 4, a week-long ... management for the 400,000 people in the United States ... "The inaugural Infusion Site Awareness Week, which ...
Cached Medicine Technology:Roche Diabetes Care Celebrates Second Annual Infusion Site Awareness Week, Aug. 29-Sept. 4 2Roche Diabetes Care Celebrates Second Annual Infusion Site Awareness Week, Aug. 29-Sept. 4 3
(Date:7/12/2014)... July 12, 2014 Utah Valley Entrepreneurial ... startups, with awards being bestowed to companies in revenue, ... outstanding entrepreneur community with recognition for new ideas as ... with incoming revenue. , 25 Under 5 highlights outstanding ... that are under 5 years old. Award recipients were ...
(Date:7/12/2014)... Restore My Vision Today is a new ... couple boasting very impressive credentials on the field of ... as a way to help consumers do without the ... respective patients’ treatments . , In particular, ... of pertinent information relevant to eye care like:, ...
(Date:7/11/2014)... 12, 2014 Recently, MagicQuinceaneraDresses.com, the popular ... new collection of 2014 Quinceanera dresses . The ... want to look fashionable without paying a large amount ... up to 57% off. , The company’s online shop ... get amazing special occasion outfits. In addition to exquisite ...
(Date:7/11/2014)... New York, New York (PRWEB) July 11, 2014 ... ( http://www.transvaginalmeshlawsuithelp.com/ ) , filed against Johnson & ... U.S. courts, Bernstein Liebhard LLP notes that the ... is investigating the company’s marketing of surgical mesh ... stress urinary incontinence. According to a report from ...
(Date:7/11/2014)... from Scientology Churches and Missions are taking ... lectures, forums and conferences, information stands, sports events, and ... , Drug abuse is an international epidemic. According to ... alcohol and illicit drugs costs more than $425 billion ... healthcare. , In the face of statistics such ...
Breaking Medicine News(10 mins):Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3
... yet another reason to reduce childhood obesity it may ... of the Journal of Allergy and Clinical Immunology ... of having some kind of allergy, especially to a food. ... Health Sciences (NIEHS) and the National Institute of Allergy and ...
... Healthcare Management Systems, Inc.(R) (HMS) announced today it ... technology provider. HMS has grown throughout the years ... currently develop, sell and support integrated clinical and financial ... decade, HMS has expanded its primary market of community ...
... in the May issue of the Journal of the ... electronic prescribing systems may allow for greater efficiency at hospitals, ... of care. , In an attempt to reduce or ... called for the use of electronic prescribing systems in all ...
... PHILADELPHIA, May 4 Children hospitalized with concussions ... clinician in a follow-up exam before returning to ... at The Children,s Hospital of Philadelphia. Rather than ... trouble signs after the initial treatment, the Children,s ...
... May 4 On Monday, May 4, Andrews ... Center at Fort Worth, will receive the "2009 ... Institute, a national women,s health conference for hospitals/health ... planning professionals. The conference offers profiles of successful ...
... Analytical, based in Ames, IA will reveal the latest results ... system. This instrument rapidly identifies microorganisms in less ... The generated fingerprint when compared to a database of ... strain typing and tracking.Because of its ease of use and ...
Cached Medicine News:Health News:New data analysis shows possible link between childhood obesity and allergies 2Health News:Healthcare Management Systems Celebrates 25 Years 2Health News:Electronic prescribing systems boost efficiency, may lead to improved quality of care 2Health News:Children with Concussions Require Follow-up Care Before Returning to Play, Say Researchers 2Health News:Children with Concussions Require Follow-up Care Before Returning to Play, Say Researchers 3Health News:Andrews Women's Hospital Receives National Recognition At Achieving Success In Women's Health Conference 2Health News:Advanced Analytical Reveals New Platform for Rapid Genotypic Identification of Microorganisms at ASM 2009 2
... X-22 Series is up to 10 inches/ 25 cm ... 11 rotors, the Allegra X-22 Series is the space-saving ... Only 18 inches / 46 cm wide • 11 ... 3 different ways to Spin 1.5 mL & ...
... centrifuges offer high-volume versatility along with a ... them ideal for a wide variety of ... Four- or six-place sealed swinging bucket rotor, ... offered , Lare capacity (4 x 750 ...
... performance centrifuge designed to accommodate over 55 ... refrigerated for heat labile samples. Incorporating the ... capability with automatic quick cooling from 22 ... min, no maintenance brushless motor, low pitch ...
Inquire...
Medicine Products: